探索抗抑郁药使用与肺癌风险之间的因果关系：孟德尔随机分析

IF 2.3 4区医学 Q3 RESPIRATORY SYSTEM

Clinical Respiratory Journal Pub Date : 2025-07-02 DOI:10.1111/crj.70102

Chunli Yang, Wenlin Xu

{"title":"探索抗抑郁药使用与肺癌风险之间的因果关系：孟德尔随机分析","authors":"Chunli Yang, Wenlin Xu","doi":"10.1111/crj.70102","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Purpose</h3>\n \n <p>The dramatic increase in antidepressant prescribing over the past decade has sparked debate about the possible contribution of antidepressants to elevated cancer risk. In this study, we investigate whether antidepressant use has a causal relationship with lung cancer risk.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Genome-wide association study (GWAS) data for antidepressant use were acquired from the FinnGen Biobank, while GWAS data for overall lung cancer and specific histological subtypes were obtained from the UK Biobank (UKBB) and IEU databases. The causal impact was evaluated using inverse variance weighting (IVW), MR-Egger regression, and weighted median (WM) approaches. Multiple sensitivity analyses were conducted to validate the findings. Results are expressed as ORs and 95% CIs.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>No causal relationship between antidepressant use and lung cancer risk was observed in the IVW (OR = 1.001, 95% CI = 0.999, <i>p</i> = 0.279), MR-Egger (OR = 1.002, 95% CI = 0.992, <i>p</i> = 0.700), and WM analyses (OR = 1.000, 95% CI: 0.997, <i>p</i> = 0.889). Similar results were found across lung cancer subtypes, including lung adenocarcinoma (LUAD) (OR = 1.197, 95% CI = 0.884–1.619, <i>p</i> = 0.247), lung squamous cell carcinoma (LUSC) (OR = 1.052, 95% CI = 0.822, <i>p</i> = 0.688), and small cell lung carcinoma (SCLC) (OR = 1.874, 95% CI = 0.737, <i>p</i> = 0.187). Sensitivity tests confirmed the robustness of these results.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>This analysis indicates antidepressant use is not significantly associated with lung cancer risk.</p>\n </section>\n </div>","PeriodicalId":55247,"journal":{"name":"Clinical Respiratory Journal","volume":"19 7","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/crj.70102","citationCount":"0","resultStr":"{\"title\":\"Exploring the Causal Relationship Between Antidepressant Use and Lung Cancer Risk: A Mendelian Randomization Analysis\",\"authors\":\"Chunli Yang, Wenlin Xu\",\"doi\":\"10.1111/crj.70102\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Purpose</h3>\\n \\n <p>The dramatic increase in antidepressant prescribing over the past decade has sparked debate about the possible contribution of antidepressants to elevated cancer risk. In this study, we investigate whether antidepressant use has a causal relationship with lung cancer risk.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Genome-wide association study (GWAS) data for antidepressant use were acquired from the FinnGen Biobank, while GWAS data for overall lung cancer and specific histological subtypes were obtained from the UK Biobank (UKBB) and IEU databases. The causal impact was evaluated using inverse variance weighting (IVW), MR-Egger regression, and weighted median (WM) approaches. Multiple sensitivity analyses were conducted to validate the findings. Results are expressed as ORs and 95% CIs.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>No causal relationship between antidepressant use and lung cancer risk was observed in the IVW (OR = 1.001, 95% CI = 0.999, <i>p</i> = 0.279), MR-Egger (OR = 1.002, 95% CI = 0.992, <i>p</i> = 0.700), and WM analyses (OR = 1.000, 95% CI: 0.997, <i>p</i> = 0.889). Similar results were found across lung cancer subtypes, including lung adenocarcinoma (LUAD) (OR = 1.197, 95% CI = 0.884–1.619, <i>p</i> = 0.247), lung squamous cell carcinoma (LUSC) (OR = 1.052, 95% CI = 0.822, <i>p</i> = 0.688), and small cell lung carcinoma (SCLC) (OR = 1.874, 95% CI = 0.737, <i>p</i> = 0.187). Sensitivity tests confirmed the robustness of these results.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>This analysis indicates antidepressant use is not significantly associated with lung cancer risk.</p>\\n </section>\\n </div>\",\"PeriodicalId\":55247,\"journal\":{\"name\":\"Clinical Respiratory Journal\",\"volume\":\"19 7\",\"pages\":\"\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-07-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/crj.70102\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Respiratory Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/crj.70102\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Respiratory Journal","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/crj.70102","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

摘要

目的：在过去十年中，抗抑郁药处方的急剧增加引发了关于抗抑郁药可能导致癌症风险升高的争论。在这项研究中，我们调查抗抑郁药的使用是否与肺癌风险有因果关系。方法从FinnGen生物银行获得抗抑郁药使用的全基因组关联研究（GWAS）数据，而从UK生物银行（UKBB）和IEU数据库获得总体肺癌和特定组织学亚型的GWAS数据。因果影响的评估采用反方差加权（IVW）、MR-Egger回归和加权中位数（WM）方法。进行多重敏感性分析以验证研究结果。结果以or和95% ci表示。结果在IVW （OR = 1.001, 95% CI = 0.999, p = 0.279）、MR-Egger （OR = 1.002, 95% CI = 0.992, p = 0.700）和WM分析（OR = 1.000, 95% CI: 0.997, p = 0.889）中均未发现抗抑郁药使用与肺癌风险之间的因果关系。在肺癌亚型中也发现了类似的结果，包括肺腺癌（LUAD）（OR = 1.197, 95% CI = 0.884-1.619, p = 0.247）、肺鳞状细胞癌（LUSC）（OR = 1.052, 95% CI = 0.822, p = 0.688）和小细胞肺癌（SCLC）（OR = 1.874, 95% CI = 0.737, p = 0.187）。敏感性试验证实了这些结果的稳健性。结论：该分析表明抗抑郁药的使用与肺癌风险无显著相关性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Exploring the Causal Relationship Between Antidepressant Use and Lung Cancer Risk: A Mendelian Randomization Analysis

查看原文本刊更多论文

Exploring the Causal Relationship Between Antidepressant Use and Lung Cancer Risk: A Mendelian Randomization Analysis

Purpose

The dramatic increase in antidepressant prescribing over the past decade has sparked debate about the possible contribution of antidepressants to elevated cancer risk. In this study, we investigate whether antidepressant use has a causal relationship with lung cancer risk.

Methods

Genome-wide association study (GWAS) data for antidepressant use were acquired from the FinnGen Biobank, while GWAS data for overall lung cancer and specific histological subtypes were obtained from the UK Biobank (UKBB) and IEU databases. The causal impact was evaluated using inverse variance weighting (IVW), MR-Egger regression, and weighted median (WM) approaches. Multiple sensitivity analyses were conducted to validate the findings. Results are expressed as ORs and 95% CIs.

Results

No causal relationship between antidepressant use and lung cancer risk was observed in the IVW (OR = 1.001, 95% CI = 0.999, p = 0.279), MR-Egger (OR = 1.002, 95% CI = 0.992, p = 0.700), and WM analyses (OR = 1.000, 95% CI: 0.997, p = 0.889). Similar results were found across lung cancer subtypes, including lung adenocarcinoma (LUAD) (OR = 1.197, 95% CI = 0.884–1.619, p = 0.247), lung squamous cell carcinoma (LUSC) (OR = 1.052, 95% CI = 0.822, p = 0.688), and small cell lung carcinoma (SCLC) (OR = 1.874, 95% CI = 0.737, p = 0.187). Sensitivity tests confirmed the robustness of these results.

Conclusions

This analysis indicates antidepressant use is not significantly associated with lung cancer risk.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical Respiratory Journal 医学-呼吸系统

CiteScore

3.70

自引率

0.00%

发文量

104

审稿时长

>12 weeks

期刊介绍： Overview Effective with the 2016 volume, this journal will be published in an online-only format. Aims and Scope The Clinical Respiratory Journal (CRJ) provides a forum for clinical research in all areas of respiratory medicine from clinical lung disease to basic research relevant to the clinic. We publish original research, review articles, case studies, editorials and book reviews in all areas of clinical lung disease including: Asthma Allergy COPD Non-invasive ventilation Sleep related breathing disorders Interstitial lung diseases Lung cancer Clinical genetics Rhinitis Airway and lung infection Epidemiology Pediatrics CRJ provides a fast-track service for selected Phase II and Phase III trial studies. Keywords Clinical Respiratory Journal, respiratory, pulmonary, medicine, clinical, lung disease, Abstracting and Indexing Information Academic Search (EBSCO Publishing) Academic Search Alumni Edition (EBSCO Publishing) Embase (Elsevier) Health & Medical Collection (ProQuest) Health Research Premium Collection (ProQuest) HEED: Health Economic Evaluations Database (Wiley-Blackwell) Hospital Premium Collection (ProQuest) Journal Citation Reports/Science Edition (Clarivate Analytics) MEDLINE/PubMed (NLM) ProQuest Central (ProQuest) Science Citation Index Expanded (Clarivate Analytics) SCOPUS (Elsevier)